The Liver Meeting 2021 (American Association for the Study of Liver Diseases)
Kowdley et al • 2021 •
© 2024 Corcept Therapeutics, Incorporated
Selective Glucocorticoid Receptor Modulation Prevents and Reverses Nonalcoholic Fatty Liver Disease in Male Mice
Koorneef et al. • 2018 • Endocrinology. 2018, 159(12):3925–3936
Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain.
Belanoff et al. • 2010 • Diabetes Obes Metab. 2010;12(6):545-7.
Selective glucocorticoid receptor antagonist CORT125281 activates brown adipose tissue and alters lipid distribution in male mice.
Kroon et al. • 2017 • Endocrinology. 2017 Sep 18. doi:10.1210/en.2017-00512.
A novel combined glucocorticoid-mineralocorticoid receptor selective modulator markedly prevents weight gain and fat mass expansion in mice fed a high-fat diet.
Mammi et al. • 2016 • Int J Obes (Lond). 2016;40(6):964-72.
Identification of a selective glucocorticoid receptor modulator that prevents both diet-induced obesity and inflammation.
van den Heuvel et al. • 2016 • Br J Pharmacol. 2016;173(11):1793-804.
Glucocorticoid antagonism limits adiposity rebound and glucose intolerance in young male rats following the cessation of daily exercise and caloric restriction.
Teich et al. • 2016 • Am J Physiol Endocrinol Metab. 2016;311(1):E56-68.
Effects of selective and non-selective glucocorticoid receptor II antagonists on rapid-onset diabetes in young rats.
Beaudry et al. • 2014 • PLoS One. 2014;9(3):e91248.
Discovery of a novel non-steroidal GR antagonist with in vivo efficacy in the olanzapine-induced weight gain model in the rat.
Hunt et al. • 2012 • Bioorg Med Chem Lett. 2012;22(24):7376-80.
Selective glucocorticoid receptor (GR-II) antagonist reduces body weight gain in mice.
Asagami et al. • 2011 • J Nutr Metab. 2011;2011:235389.